Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: TRIMM-2 Study

C. Ola Landgren, MD, PhD, and Noopur Raje, MD, discussed results from the ADVANCE trial of DKRd in patients with newly diagnosed multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.